Delays Related to Prior Authorization in Inflammatory Bowel Disease

Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations

(2021) Gregor J. Dudiak et al.   ALLERGY AND ASTHMA PROCEEDINGS

Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study

(2020) Johan Burisch et al.   Lancet Gastroenterology & Hepatology

Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study

(2020) S. Philipp et al.   BRITISH JOURNAL OF DERMATOLOGY

Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting

(2020) B. Bokemeyer et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children

(2020) Véronique Minard-Colin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Administrative Burden and Costs of Prior Authorizations in a Dermatology Department

(2020) Ryan P. Carlisle et al.   JAMA Dermatology

Advocating for Patients With Inflammatory Bowel Disease: How to Navigate the Prior Authorization Process

(2019) Shubha Bhat et al.   INFLAMMATORY BOWEL DISEASES

The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation

(2019) K T Park et al.   INFLAMMATORY BOWEL DISEASES

The REDCap consortium: Building an international community of software platform partners

(2019) Paul A. Harris et al.   JOURNAL OF BIOMEDICAL INFORMATICS

Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study

(2019) Zachary S. Wallace et al.   ARTHRITIS CARE & RESEARCH

Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis

(2018) Siddharth Singh et al.   Journal of Crohns & Colitis

Impact of Prior Authorization of Antiepileptic Drugs in Children With Epilepsy

(2018) Elaine C. Wirrell et al.   PEDIATRIC NEUROLOGY

Early Initiation of Tumor Necrosis Factor Antagonist-based Therapy for Patients with Crohn’s Disease Reduces Costs Compared With Late Initiation

(2018) Candace L. Beilman et al.   Clinical Gastroenterology and Hepatology

Systematic review and network meta-analysis Medical therapies to prevent recurrence of post-operative Crohn’s disease

(2018) Nicholas E Burr et al.   Journal of Crohns & Colitis

Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization

(2017) Ravy K Vajravelu et al.   INFLAMMATORY BOWEL DISEASES

Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study

(2017) Subra Kugathasan et al.   LANCET

Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study

(2017) Akbar K Waljee et al.   BMJ-British Medical Journal

Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study

(2017) Akbar K Waljee et al.   BMJ-British Medical Journal

Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease

(2017) Amir Rumman et al.   Canadian Journal of Gastroenterology and Hepatology

The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation

(2016) Jonathan Shepherd et al.   HEALTH TECHNOLOGY ASSESSMENT

Incidence of Bowel Surgery and Associated Risk Factors in Pediatric-Onset Crohnʼs Disease

(2016) Firas Rinawi et al.   INFLAMMATORY BOWEL DISEASES

Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease

(2016) Benjamin Click et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Medication prior authorization in pediatric hematology and oncology

(2016) David S. Dickens et al.   PEDIATRIC BLOOD & CANCER

Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn’s Disease: A Retrospective Cohort Study

(2015) Yago González-Lama et al.   Journal of Crohns & Colitis

Biologic agents for IBD: practical insights

(2015) Silvio Danese et al.   Nature Reviews Gastroenterology & Hepatology

Methods for Constructing and Assessing Propensity Scores

(2014) Melissa M. Garrido et al.   HEALTH SERVICES RESEARCH

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease

(2014) J Dretzke et al.   HEALTH TECHNOLOGY ASSESSMENT

Diagnostic Delay in Crohn's Disease Is Associated With a Complicated Disease Course and Increased Operation Rate

(2013) Alain M Schoepfer et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease

(2013) Thomas D. Walters et al.   GASTROENTEROLOGY

Infliximab Reduces Hospitalizations and Surgery Interventions in Patients With Inflammatory Bowel Disease

(2013) João Costa et al.   INFLAMMATORY BOWEL DISEASES

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Applying Propensity Score Methods in Medical Research: Pitfalls and Prospects

(2010) Zhehui Luo et al.   MEDICAL CARE RESEARCH AND REVIEW

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

(2009) Peter C. Austin   STATISTICS IN MEDICINE